Corcept Gross Profit from 2010 to 2024

CORT Stock

USD 52.42 2.72 4.93%

Corcept Therapeutics Gross Profit yearly trend continues to be comparatively stable with very little volatility. Gross Profit is likely to outpace its year average in 2024. Gross Profit is the profit Corcept Therapeutics Incorporated makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. View All Fundamentals

Gross Profit

First Reported

2000-03-31

Previous Quarter

161.3 M

Current Value

179.7 M

Quarterly Volatility

45.9 M

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check Corcept Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Corcept Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 4.3 M, Selling General Administrative of 193.1 M or Research Development of 193.6 M, as well as many indicators such as Price To Sales Ratio of 6.62, Dividend Yield of 0.0 or PTB Ratio of 6.97. Corcept financial statements analysis is a perfect complement when working with Corcept Therapeutics Valuation or Volatility modules.

Check out the analysis of Corcept Therapeutics Correlation against competitors.

Latest Corcept Therapeutics' Gross Profit Growth Pattern

Below is the plot of the Gross Profit of Corcept Therapeutics Incorporated over the last few years. Gross profit is a required income statement account that reflects total revenue of Corcept Therapeutics Incorporated minus its cost of goods sold. It is profit before Corcept Therapeutics operating expenses, interest payments and taxes. Gross profit is also known as gross margin. It is the profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. Corcept Therapeutics' Gross Profit historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Corcept Therapeutics' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 396.47 M

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Gross Profit

Timeline

Corcept Gross Profit Regression Statistics

	Arithmetic Mean	196,752,447
	Geometric Mean	0.00
	Coefficient Of Variation	94.98
	Mean Deviation	166,772,210
	Median	155,647,000
	Standard Deviation	186,870,721
	Sample Variance	34920.7T
	Range	499.7M
	R-Value	0.97
	Mean Square Error	2165.6T
	R-Squared	0.94
	Slope	40,564,628
	Total Sum of Squares	488889.3T

Corcept Gross Profit History

	2024	499.7 M
	2023	475.9 M
	2022	396.5 M
	2021	360.7 M
	2020	348.3 M
	2019	301 M
	2018	246 M

Other Fundumenentals of Corcept Therapeutics

Gross Profit Margin

Corcept Therapeutics Gross Profit component correlations

	Total Assets	Accounts Payable	Total Liab	Common Stock	Property Plant Equipment	Total Stockholder Equity	Short Term Investments	Net Debt	Retained Earnings	Total Current Assets	Current Deferred Revenue	Short Term Debt	Net Tangible Assets	Capital Surpluse	Net Receivables	Long Term Debt Total	Short Long Term Debt	Net Invested Capital	Long Term Investments	Net Working Capital	Capital Stock
Total Assets		0.93	0.82	0.5	0.98	1.0	0.93	-0.76	0.9	0.99	0.86	-0.54	1.0	0.86	0.93	-0.6	0.7	0.96	0.46	0.94	0.86
Accounts Payable	0.93		0.89	0.43	0.94	0.91	0.79	-0.51	0.87	0.87	0.89	-0.55	0.93	0.75	0.94	-0.5	0.64	0.83	0.34	0.8	0.87
Total Liab	0.82	0.89		0.43	0.88	0.76	0.64	-0.34	0.8	0.76	0.77	-0.32	0.81	0.71	0.82	-0.38	0.54	0.75	0.34	0.7	0.92
Common Stock	0.5	0.43	0.43		0.44	0.48	0.47	-0.53	0.18	0.51	0.38	0.16	0.44	0.69	0.49	-0.7	0.64	0.46	0.27	0.45	0.27
Property Plant Equipment	0.98	0.94	0.88	0.44		0.97	0.9	-0.67	0.92	0.96	0.86	-0.51	0.98	0.83	0.92	-0.54	0.65	0.95	0.42	0.93	0.91
Total Stockholder Equity	1.0	0.91	0.76	0.48	0.97		0.95	-0.8	0.9	0.99	0.85	-0.57	1.0	0.85	0.92	-0.61	0.7	0.96	0.46	0.94	0.83
Short Term Investments	0.93	0.79	0.64	0.47	0.9	0.95		-0.89	0.79	0.96	0.71	-0.49	0.93	0.79	0.79	-0.59	0.63	0.95	0.28	0.98	0.7
Net Debt	-0.76	-0.51	-0.34	-0.53	-0.67	-0.8	-0.89		-0.58	-0.84	-0.47	0.42	-0.74	-0.72	-0.57	0.56	-0.51	-0.81	-0.36	-0.84	-0.44
Retained Earnings	0.9	0.87	0.8	0.18	0.92	0.9	0.79	-0.58		0.88	0.83	-0.68	0.92	0.77	0.86	-0.38	0.52	0.88	0.53	0.83	0.94
Total Current Assets	0.99	0.87	0.76	0.51	0.96	0.99	0.96	-0.84	0.88		0.81	-0.53	0.98	0.87	0.88	-0.6	0.68	0.98	0.48	0.96	0.82
Current Deferred Revenue	0.86	0.89	0.77	0.38	0.86	0.85	0.71	-0.47	0.83	0.81		-0.39	0.87	0.76	0.94	-0.66	0.78	0.75	0.45	0.71	0.81
Short Term Debt	-0.54	-0.55	-0.32	0.16	-0.51	-0.57	-0.49	0.42	-0.68	-0.53	-0.39		-0.58	-0.33	-0.44	-0.14	0.02	-0.51	-0.34	-0.48	-0.48
Net Tangible Assets	1.0	0.93	0.81	0.44	0.98	1.0	0.93	-0.74	0.92	0.98	0.87	-0.58		0.84	0.93	-0.59	0.69	0.95	0.47	0.93	0.86
Capital Surpluse	0.86	0.75	0.71	0.69	0.83	0.85	0.79	-0.72	0.77	0.87	0.76	-0.33	0.84		0.83	-0.74	0.78	0.87	0.58	0.82	0.73
Net Receivables	0.93	0.94	0.82	0.49	0.92	0.92	0.79	-0.57	0.86	0.88	0.94	-0.44	0.93	0.83		-0.69	0.79	0.82	0.47	0.78	0.85
Long Term Debt Total	-0.6	-0.5	-0.38	-0.7	-0.54	-0.61	-0.59	0.56	-0.38	-0.6	-0.66	-0.14	-0.59	-0.74	-0.69		-0.96	-0.55	-0.3	-0.54	-0.35
Short Long Term Debt	0.7	0.64	0.54	0.64	0.65	0.7	0.63	-0.51	0.52	0.68	0.78	0.02	0.69	0.78	0.79	-0.96		0.63	0.36	0.6	0.51
Net Invested Capital	0.96	0.83	0.75	0.46	0.95	0.96	0.95	-0.81	0.88	0.98	0.75	-0.51	0.95	0.87	0.82	-0.55	0.63		0.45	0.99	0.81
Long Term Investments	0.46	0.34	0.34	0.27	0.42	0.46	0.28	-0.36	0.53	0.48	0.45	-0.34	0.47	0.58	0.47	-0.3	0.36	0.45		0.31	0.5
Net Working Capital	0.94	0.8	0.7	0.45	0.93	0.94	0.98	-0.84	0.83	0.96	0.71	-0.48	0.93	0.82	0.78	-0.54	0.6	0.99	0.31		0.76
Capital Stock	0.86	0.87	0.92	0.27	0.91	0.83	0.7	-0.44	0.94	0.82	0.81	-0.48	0.86	0.73	0.85	-0.35	0.51	0.81	0.5	0.76

Click cells to compare fundamentals

About Corcept Therapeutics Financial Statements

Corcept Therapeutics shareholders use historical fundamental indicators, such as Gross Profit, to determine how well the company is positioned to perform in the future. Although Corcept Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Corcept Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Corcept Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

	Last Reported	Projected for Next Year
Gross Profit	475.9 M	499.7 M
Gross Profit Margin	0.99	0.78

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Corcept Stock Analysis

When running Corcept Therapeutics' price analysis, check to measure Corcept Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corcept Therapeutics is operating at the current time. Most of Corcept Therapeutics' value examination focuses on studying past and present price action to predict the probability of Corcept Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corcept Therapeutics' price. Additionally, you may evaluate how the addition of Corcept Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC